| Literature DB >> 30923040 |
Emanuela M Ghia1, Laura Z Rassenti1, Donna S Neuberg2, Alejandro Blanco3, Fouad Yousif4, Erin N Smith5, John D McPherson6, Thomas J Hudson4, Olivier Harismendy1,7, Kelly A Frazer1,5, Thomas J Kipps1.
Abstract
Targeted sequencing of 103 leukemia-associated genes in leukemia cells from 841 treatment-naive patients with chronic lymphocytic leukemia (CLL) identified 89 (11%) patients as having CLL cells with mutations in genes encoding proteins that putatively are involved in hedgehog (Hh) signaling. Consistent with this finding, there was a significant association between the presence of these mutations and the expression of GLI1 (χ2 test, P < .0001), reflecting activation of the Hh pathway. However, we discovered that 38% of cases without identified mutations also were GLI1+ Patients with GLI1+ CLL cells had a shorter median treatment-free survival than patients with CLL cells lacking expression of GLI1 independent of IGHV mutation status. We found that GANT61, a small molecule that can inhibit GLI1, was highly cytotoxic for GLI1+ CLL cells relative to that of CLL cells without GLI1. Collectively, this study shows that a large proportion of patients have CLL cells with activated Hh signaling, which is associated with early disease progression and enhanced sensitivity to inhibition of GLI1.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30923040 PMCID: PMC6587306 DOI: 10.1182/blood-2018-09-873695
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 25.476